Trinity Biotech

Trinity Biotech EBIT Growth

The Year-over-Year EBIT Growth of Trinity Biotech (TRIB) as of Oct 16, 2026 is 46.06 %. In the previous year, Year-over-Year EBIT Growth was 21.74 % — a change of 111.86% (higher).

EBIT Growth

46.06 %

YoY

111.86%

Last updated:

Year-over-Year EBIT Growth of Trinity Biotech is 2025 46.06 % . Year-over-Year EBIT Growth of Trinity Biotech was 2024 21.74 % . It decreases by 111.86% higher compared to the previous year.

The Trinity Biotech EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
-39.81 USD
Jan 1, 2019
-73.55 USD
Jan 1, 2020
-90.60 USD
Jan 1, 2021
4,702.44 USD
Jan 1, 2022
-487.73 USD
Jan 1, 2023
-77.12 USD
Jan 1, 2024
21.74 USD
Jan 1, 2025
46.06 USD
The Trinity Biotech EBIT Growth history
YEAREBIT GrowthYoY
46.06 %+111.86%
21.74 %-128.19%
-77.12 %-84.19%
-487.73 %-110.37%
4,702.44 %-5,290.54%
-90.60 %+23.17%
-73.55 %+84.74%
-39.81 %+48.16%
-26.87 %-39.34%
-44.30 %+74.10%
-25.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech PLC is a healthcare company based in Bray, Ireland, with a focus on developing, manufacturing, and marketing medical diagnostic products. The company serves the clinical laboratory and point-of-care segments of the diagnostic market. Trinity Biotech employs 579 full-time staff and has been publicly traded since its IPO on October 21, 1992. Its products are designed to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company operates through two geographic segments: the Americas and Rest of World. Product categories include point-of-care diagnostics, emergency medicine diagnostics, clinical laboratory reagents, and blood bank screening. The company's point-of-care brands are Uni-Gold and Recombigen, while its emergency medicine diagnostics cover acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. Trinity Biotech supplies the clinical laboratory market with reagent products and other solutions through its clinical chemistry business. The blood bank screening division manufactures products to screen donated blood for transfusion-transmissible infections. The company's website is www.trinitybiotech.com. Trinity Biotech PLC is listed on the stock market under the ticker TRIB and ISIN US8964385046. The company's headquarters are located in Bray, Wicklow, Ireland. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Year-over-Year EBIT Growth of Trinity Biotech is 46.06 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Trinity Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Trinity Biotech

All Key Metrics — Trinity Biotech